BackNgm Biopharmaceuticals Overview

Ngm Biopharmaceuticals Long Term Debt

Track Ngm Biopharmaceuticals's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Ngm Biopharmaceuticals Long Term Debt History

Loading

Ngm Biopharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Ngm Biopharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ngm Biopharmaceuticals (NGM) FAQ

The latest long-term debt for NGM is $0 as of December 2023. In the prior-year period, the figure was $0. Investors often review this figure alongside Ngm Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, NGM's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ngm Biopharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $0 for NGM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NGM's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ngm Biopharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.